ALFIERI CARDIOLOGY
PREVENTION & INNOVATION

G-39 Omega Drive • Newark, DE 19713 • (302) 731-0001

December 5, 2013

To: Lester Tripp
USNRC Region 1

Re: Request for Additional Information in Support of License Renewal
License No. 07-28154-01
Control No. 581465

Dear Mr. Tripp,

In reply to your email request for additional information, dated November 20, 2013, please find the responses below:

1. Your current License Amendment No. 7 specifies the name of your facility as *Alfieri Cardiology, P.A., d.b.a. Delaware SPECT Imaging*. On NRC Form 313, your application states that the name of your facility is *Alfieri Cardiology P.A.* Please specify the correct name of your facility. Also state whether there has been a change of control/ownership of your facility.

The correct name of the facility is **Alfieri Cardiology, P.A.** There has been no change of control or ownership of the facility.

2. Your current License Amendment No. 7 authorizes the possession and use of radiopharmaceuticals permitted by 10 CFR 35.100 and 10 CFR 35.200. In items Number 5 and Number 6 of your renewal application you request only 10 CFR 35.200. Do you want to discontinue authorization for possession and use of radiopharmaceuticals permitted by 10 CFR 35.100?

Yes, please discontinue authorization for radiopharmaceuticals permitted by 10 CFR 35.100, as we are no longer performing any nuclear medicine uptake, dilution or excretion studies.

3. Item 7, paragraph 4 of your application, refers to 10 CFR 20.110. The correct reference is 10 CFR 20.1101. Please confirm that you have developed and will implement and maintain written procedures for safe response to spills of licensed material in accordance with 10 CFR 20.1101.

We have developed, implemented and will maintain written procedures for safe response to spills of licensed material in accordance with 10 CFR 20.1101.

4. Item 7, paragraph 5 of your application, should specify that the required procedures will be ***written***. Please confirm that you have developed and will implement and maintain ***written*** procedures for safe use of unsealed byproduct material that meet the requirements of 10 CFR 20.1101 and 10 CFR 20.1301.

> We have developed and will implement and maintain written procedures for safe use of unsealed radioactive material that meet the requirements of 10 CFR 20.1101 and 10 CFR 20.1301.

5. Item 7, paragraph 2 of your application, references *Appendix N Model Procedures for Developing, Maintaining, and Implementing Written Directives.* (Written directive references are in Appendix S). Written Directives are only required for certain therapeutic use of license material, therefore no confirmation involving written directives is required.

> No response.

Please contact me if you need any further information.

Sincerely,

Paul J. Alfieri, MD, FACC
Cardiologist

PJA/jm